Gemcitabine confirmed as the first-line therapy for pancreatic cancer

被引：3
|
作者：
Claire Greenhill
机构：
来源：
Nature Reviews Gastroenterology & Hepatology | 2011年 / 8卷 / 1期
关键词：
D O I：
10.1038/nrgastro.2010.200
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：3 / 3
相关论文
共 50 条
  • [21] Prognostic Factors in Japanese Patients with Advanced Pancreatic Cancer Treated with Single-agent Gemcitabine as First-line Therapy
    Tanaka, Tsutomu
    Ikeda, Masafumi
    Okusaka, Takuji
    Ueno, Hideki
    Morizane, Chigusa
    Hagihara, Atsushi
    Iwasa, Satoru
    Kojima, Yasushi
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2008, 38 (11) : 755 - 761
  • [22] A phase II study of gemcitabine plus nab-paclitaxel as first-line therapy for locally advanced pancreatic cancer
    Fukahori, Masaru
    Miwa, Keisuke
    Murotani, Kenta
    Naito, Yoshiki
    Ushijima, Tomoyuki
    Sakaue, Takahiko
    Tanaka, Toshimitsu
    Nagasu, Sachiko
    Suga, Hideya
    Kakuma, Tatsuyuki
    Okabe, Yoshinobu
    Torimura, Takuji
    MEDICINE, 2021, 100 (20) : E26052
  • [23] FOLFIRINOX versus Gemcitabine/nabPaclitaxel as First-line palliative Therapy in advanced Pancreatic Cancer: a Propensity-Score Analysis
    Riedl, Jakob M.
    Posch, Florian
    Gantschnigg, Antonia
    Horvath, Lena
    Renneberg, Felix
    Schwarzenbacher, Esther
    Moik, Florian
    Barth, Dominik
    Stotz, Michael
    Schaberl-Moser, Renate
    Pichler, Martin
    Stoeger, Herbert
    Greil, Richard
    Djanani, Angela
    Schlick, Konstantin
    Gerger, Armin
    WIENER KLINISCHE WOCHENSCHRIFT, 2020, 132 : 78 - 79
  • [24] Bevacizumab plus gemcitabine and oxaliplatin as first-line therapy for metastatic or locally advanced pancreatic cancer: a phase II trial
    Fogelman, David
    Jafari, Mehrdad
    Varadhachary, Gauri R.
    Xiong, Henry
    Bullock, Susie
    Ozer, Harold
    Lin, E.
    Morris, Jeffrey
    Cunningham, Patti
    Bennett, Bronwyn
    Abbruzzese, James L.
    Wolff, Robert A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (06) : 1431 - 1438
  • [25] Impact of somatic KRAS Mutations on the First-line Therapy in Pancreatic Cancer
    Bochum, S.
    Vladimirova, D.
    Akkad, J.
    Weiss, M.
    Martens, U.
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 224 - 224
  • [26] First-line chemotherapy in very elderly patients with metastatic pancreatic cancer: Gemcitabine monotherapyvscombination chemotherapy
    Han, Sung Yong
    Kim, Dong Uk
    Seol, Young Mi
    Kim, Suk
    Lee, Nam Kyung
    Hong, Seung Baek
    Seo, Hyung-Il
    WORLD JOURNAL OF CLINICAL CASES, 2020, 8 (18) : 4022 - 4033
  • [27] Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer
    Su, Dan
    Jiao, Shun-Chang
    Wang, Li-Jie
    Shi, Wei-Wei
    Long, Yan-Yan
    Li, Juan
    Bai, Li
    TUMOR BIOLOGY, 2014, 35 (03) : 2313 - 2318
  • [28] First-line chemotherapy with gemcitabine in advanced pancreatic cancer: a retrospective single-center analysis
    Magalhaes, H.
    Cassiano Neves, M.
    Fontes e Sousa, M.
    Machado, M.
    Marques, D.
    Faustino, C.
    Sousa, N.
    Ferreira, P.
    Raimundo, A.
    Fragoso, M.
    Luis, M.
    Sales, C.
    ANNALS OF ONCOLOGY, 2015, 26
  • [29] NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
    Nichetti, Federico
    Rota, Simone
    Ambrosini, Paolo
    Pircher, Chiara
    Gusmaroli, Eleonora
    Busset, Michele Droz Dit
    Pusceddu, Sara
    Sposito, Carlo
    Coppa, Jorgelina
    Morano, Federica
    Pietrantonio, Filippo
    Di Bartolomeo, Maria
    Mariani, Luigi
    Mazzaferro, Vincenzo
    de Braud, Filippo
    Niger, Monica
    JAMA NETWORK OPEN, 2024, 7 (01)
  • [30] Immunomodulatory effects of lenalidomide in combination with gemcitabine as first-line treatment in patients with advanced pancreatic cancer
    Liljefors, M.
    Mozaffari, F. S.
    Mellstedt, H.
    Ullenhag, G.
    ANNALS OF ONCOLOGY, 2015, 26 : 12 - 12
12345